Search

Your search keyword '"Kaddu‐Mulindwa, Dominic"' showing total 193 results

Search Constraints

Start Over You searched for: Author "Kaddu‐Mulindwa, Dominic" Remove constraint Author: "Kaddu‐Mulindwa, Dominic"
193 results on '"Kaddu‐Mulindwa, Dominic"'

Search Results

1. An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma

4. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

6. Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.

7. Comparison of R‐CHOP‐14 and R‐mini‐CHOP in older adults with diffuse large B‐cell lymphoma—A retrospective multicenter cohort study.

8. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials

9. LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

10. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

16. A dynamic time‐to‐event model for prediction of acute graft‐versus‐host disease in patients after allogeneic hematopoietic stem cell transplantation

18. Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP

19. Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells

20. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

21. Adaptive humoral immune response and cellular immune status in cancer patients and patients under immunosuppression vaccinated against SARS-CoV-2

27. Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients

28. Cost‑effectiveness of precision cancer medicine‑current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review)

30. IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study

32. Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial

33. Autoantibodies against Progranulin and IL-1 receptor antagonist due to immunogenic posttranslational isoforms contribute to hyperinflammation in critically ill COVID-19

34. A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

35. Additional file 1 of Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019

36. The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells

38. Pneumocystis Jirovecii Pneumonia and SARS-CoV-2 Co-Infection in newly diagnosed HIV-1 infection

39. Increased B‐cell activity with consumption of activated monocytes in severe COVID‐19 patients

40. Drug adherence and psychosocial characteristics of patients presenting with hypertensive urgency at the emergency department

41. Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis

42. IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study.

43. Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma

45. Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab

46. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy

47. Pneumocystis jirovecii Pneumonia and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection in a Patient With Newly Diagnosed HIV-1 Infection

49. Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.

Catalog

Books, media, physical & digital resources